RxDoctor Payments Data

Aalok Patel, MD

Interventional Cardiology · Orlando, FLNPI 1265759898

Payments from drug & device makers

$114,936in general payments, 2019–2025

Across 154 payments — averaging $746.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Angiodynamics, Inc.$107K
  • Altathera Pharmaceuticals LLC$2K
  • Abbott$1K
  • Biotronik Inc.$825
  • Kestra Medical Technology Services, Inc.$733
  • Abiomed$544
  • plus $3K from 34 others

What the payments were for

  • Speaking & faculty fees$1,5001%
  • Food & beverage$6,0945%
  • Education$140%
  • Other$107,32993%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$114,936 in reported general payments places this provider in the 80th percentile of 623 interventional cardiology providers in Florida.

See all interventional cardiology providers in Florida

Medicare billing

Part B allowed, 2024
$2,033,713
Medicare patients
663
Services billed
13,655

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban110$113,400
EntrestoSacubitril/Valsartan38$48,100
JardianceEmpagliflozin36$42,630
Repatha SureclickEvolocumab17$16,380
BrilintaTicagrelor11$9,161
Repatha SyringeEvolocumab13$8,254
Amiodarone Hcl44$1,719
Midodrine Hcl18$1,656
Metoprolol Succinate139$1,444
Rosuvastatin Calcium65$1,401
Nebivolol Hcl26$1,322
ClopidogrelClopidogrel Bisulfate99$1,310
Losartan Potassium112$1,134
Bumetanide44$1,114
Amlodipine Besylate168$1,028

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$124$113,400110 claims
NovartisEntresto$73$48,10038 claims
Boehringer IngelheimJardiance$495$42,63036 claims
AstraZenecaBrilinta$89$9,16111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 623 interventional cardiology providers in Florida.

Other interventional cardiology in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →